Junsei Bio's GC101 TIL Key Phase II Investigator Meeting Successfully Convenes

Mar 15, 2025 23:59 CST Updated 23:59

Juncell Therapeutics

Solid Tumor Cell Therapy Developer

On March 15, 2025, sponsored by Shanghai Juncell Therapeutics (referred to as "Juncell Therapeutics"),Peking University Cancer Hospital as the Group Leader UnitOf"A Multicenter, Randomized Controlled, Open-label, Phase II Clinical Trial (MIZAR-003) of Autologous Natural Tumor Infiltrating Lymphocyte Injection (GC101 TIL) for the Treatment of Advanced Melanoma Patients"Investigator MeetingIn BeijingSuccessfully convened. This is currently one of the most highly anticipated developments in the field of solid tumor cell therapy.Key Phase II Clinical Study。

Prof. Guo Jun from Peking University Cancer Hospital and Dr. Jin Huajun, founder of Juncell Therapeutics, delivered the opening remarks. More than 60 research experts from across China attended the investigator meeting to discuss new developments in TIL cell therapy research for melanoma in China.

Based on the data from the GC101 TIL pivotal Phase II clinical trial, Juncell Therapeutics will provide options for melanoma patients in China.Best-in-Class GloballyTIL CellsNewly Listed Drugs, Reshaping the Treatment Landscape for Melanoma.

MIZAR-003 Project

HopefulReshaping the Treatment Landscape for Advanced Melanoma

GC101 TIL is the world's firstNo need for lymphodepletion, no need for IL-2 injectionThe natural TIL therapy,Relying on Juncell Therapeutics' independently developed, globally leading DeepTIL^®Cell Enrichment and Expansion Platform (Dual-free (ex vivo feeder cell & in vivo IL-2 free) expansion with optimized potency) developed,Endow TIL CellsDeep into the tumorCapable of exerting highly efficient cytotoxicity, ensuring benefits for patientsDeep and LastingThe efficacy.

Different from the numerous adverse reactions caused by the need for high-intensity lymphodepletion chemotherapy and repeated high-dose IL-2 injections, leading toLifileucel, which has been given a black box warning by the FDA, GC101 TIL Clinical ApplicationNo need for clear infusionAndInjection of IL-2 at any dose。

Early clinical studies show that the objective response rate (ORR) of GC101 for various types of advanced solid tumorsOver 35%, already hasMultiple CasesThe patient's tumor was completely cleared, achievingComplete Remission (CR)Efficacy, with the longest tumor-free survival time alreadyOver 3 years。AndAlthough the subjects of GC101 are mainly more difficult to treatAcral and Mucosal TypesIn patients with melanoma, the objective response rate (ORR) of GC101 TIL is similar to that of Lifileucel, and the median progression-free survival (mPFS) is extended by more than one month.

In terms of safety, compared to Lifileucel, the subjects of GC101 inGeneral WardNo treatment-related deaths or ICU admissions occurred, and no patients required blood cell transfusions, with hospital stays reduced by approximately 80%.

MIZAR-003 ProjectAimed to evaluate the efficacy and safety of GC101 TIL cell therapy in patients with advanced melanoma. A total of 24 centers across China participated in the study, bringing together leading institutions and experts in the field of melanoma to jointly advance the project and provide more clinical benefit evidence for melanoma patients.Clinical Recruitment | Juncell Therapeutics GC101 TIL in the Ongoing Pivotal Phase II Clinical Trial for Melanoma）

"Tumor-Infiltrating Lymphocyte (TIL) therapy has made breakthrough progress in the treatment of advanced melanoma, laying the foundation for the future comprehensive treatment of melanoma."Professor Guo JunRepresentative: "Juncell Therapeutics' GC101 TIL has demonstrated favorable safety and efficacy in early clinical trials, distinct from traditional TIL therapies, enhancing clinical management convenience and further improving patient accessibility. We look forward to the pivotal Phase II clinical trial data of GC101 TIL showing continued positive efficacy, bringing new hope to Chinese patients with advanced melanoma."

Dr. Jinhua JunJuncell Therapeutics has achieved a series of groundbreaking innovative results through long-term exploration and practice in the field of TIL cell therapy. It is expected that the pivotal Phase II clinical trial of GC101 TIL will effectively address the treatment challenges faced by patients with advanced melanoma. Juncell Therapeutics will fully support the investigators in advancing the MIZAR-003 project and work together with all partners to benefit more patients with advanced melanoma.

At the meeting, experts conducted a comprehensive and detailed discussion on the pivotal Phase II clinical trial of GC101 TIL injection for melanoma, laying a solid foundation for the smooth progress of the MIZAR-003 project.

While traditional consumer rights protection focuses on the authenticity of goods and fair pricing, Juncell Therapeutics, through this special 315-period investigator meeting, elevates biopharmaceutical R&D to the level of safeguarding the quality of life. As China’s technological strength gradually gains recognition on the international stage, Juncell Therapeutics is building a consensus of values: in the life-and-death field of innovative drug development, the highest form of rights protection is ensuring that every life can benefit from the new hope brought by technological advancement.

The convening of the MIZAR-003 project investigator meeting will strongly ensure the smooth progress of the GC101 TIL pivotal Phase II clinical trial, contributing to the advancement of melanoma diagnosis and treatment worldwide.

This article is original from Global Cancer Doctors Network. Reproduction is strictly prohibited without authorization.

Scan to Add Patient Group

Cancer Information｜New Technologies｜New Drug Development｜Leading Experts

Join the group to receive free anti-cancer resources

Cellular Immunity